Firms:Dibbsbarker (Regeneus Ltd)
Deal: Biotechnology company Regeneus’ listing on the Australian Stock Exchange (ASX)
Area: Equity Capital Markets
Value: The company’s IPO raised $10.5 million at $0.25 per share, which valued the company at $45.9 million upon listing
Key players: The DibbsBarker team was led by commercial partners Geoff Cairns and Lis Boyce (pictured)
Deal significance:This is the first listing of a biotechnology company on the ASX since 2011 Regeneus, which was founded in 2007, isa Sydney-based regenerative medicine company. The funds raised by the IPO will bolster the company’s research and development efforts and assist in the commercialisation of new technologies and therapies.
Like this story? Read more: